Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.
Bellmunt Risk Score Validated as Independent Prognostic Tool Across mCRPC Treatment Lines — A three-point clinical scoring system predicted overall survival with striking discrimination in two large phase 3 trial cohorts: men with metastatic castration-resistant prostate cancer scoring 3 on the Bellmunt Risk Score faced more than eight times the mortality hazard of those scoring 0 in the first-line setting (AHR 8.